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Plasma?Ceruloplasmin,?a?Regulator?of?Nitric?Oxide
Activity,?and? Incident?Cardiovascular?Risk? in?Patients
with?CKD
David? J.?Kennedy,?Yiying?Fan,Yuping?Wu,?Michael?Pepoy?? Stanley?L.?Hazen,? and?W.H.?Wilson?Tang
Abstract
Background?and?objectives?Increased?serum?levels?of?the?acute-phase?reactant?ceruloplasmin?predict?adverse?
clinical?outcomes?in?the?setting?of?acute?coronary?syndromes?and?heart?failure,?but?their?role?in?patients?with?CKD?
is?unclear.?This?study?investigated?the?relationship?of?ceruloplasmin?with?clinical?outcomes?in?CKD,?especially?
with?regard?to?traditional?cardiac?biomarkers.
Design,?setting,?participants,?&?measurements?Serum?ceruloplasmin?levels?in?consecutive?study?participants?with?
CKD?(n=654;?estimated?GFR,60?ml/min?per?1.73?m2)?as?well?as?a?control?group?of?non-CKD?participants?
matched?for?age?and?sex?(n=250)?were?measured.?Study?participants?were?enrolled?during?2001? 2006?from?a?
population?of?patients?presenting?for?elective?diagnostic?coronary?angiography?and?prospectively?followed?for?
3?years?(median?follow-up=1095?days)?to?determine?incident?major?adverse?cardiac?events?(deﬁned?as?a?
composite?of?death,?nonfatal?myocardial?infarction,?and?stroke).
Results?Serum?ceruloplasmin?levels?in?CKD?patients?were?elevated?versus?controls?(median?[interquartile?range];?
25.5?[21.8? 29.6]?versus?22.7?[19.7? 26.5]?mg/dl;?P,0.001)?and?associated?with?increased?risk?of?future?major?
adverse?cardiac?events?(hazard?ratio,?1.35;?95%?conﬁdence?interval,?1.0?to?1.82;?P=0.04).?After?adjusting?for?
traditional?risk?factors,?higher?serum?ceruloplasmin?was?still?associated?with?higher?risk?of?major?adverse?cardiac?
events?at?3?years?(hazard?ratio,?1.61;?95%?conﬁdence?interval,?1.15?to?2.25;?P=0.01).
Conclusion?In?CKD?patients,?increased?serum?ceruloplasmin,?a?regulator?of?nitric?oxide?activity,?is?associated?with?
increased?risk?of?long-term?adverse?cardiovascular?events,?even?after?multivariable?model?adjustment?for?
traditional?clinical?and?biologic?risk?factors.
Introduction
CKD is a nitric oxide (NO)-deﬁcient state (1), and the
associated oxidative stress contributes to not only the
progression of renal injury, but also its attendant car-
diovascular complications (2). NO imbalance can pro-
mote inﬂammation, oxidant stress, endothelial
dysfunction, and tissue injury, and it is a potential
contributor to both CKD and cardiovascular disease
progression.
Ceruloplasmin (Cp) is an acute-phase reactant that
is synthesized and secreted by the liver as well as
monocyte/macrophages, and it participates in both
iron and copper metabolism (3). Recently, both anti-
oxidant and pro-oxidant activities of Cp have been
shown and suggest a role for Cp in regulating NO
homeostasis (4). In vitro, Cp shows NO oxidase activ-
ity by catalytic consumption of NO, whereas Cp im-
munodepletion, Cp knockout mice, and humans with
congenital aceruloplasminemia all show diminished
plasma NO oxidase activity (4). Several studies have
also connected Cp levels with increased cardiovascu-
lar risk in both the normal population (5 7) and
patients with acute coronary syndromes (8,9). In par-
ticular, our group has shown the prognostic value of
elevated Cp, even after adjustment for traditional risk
factors, for determining the future risk of cardiac
events in stable cardiac patients (10).
Despite signiﬁcant evidence that enhanced oxida-
tive and nitrative stresses are present in patients with
CKD and ESRD, the underlying pathways involved in
this imbalance remain a topic of active investigation.
In this study, we sought to establish the possible role
of serum Cp in predicting incident adverse clinical
outcomes, including myocardial infarction (MI),
stroke, and death, among patients with moderate
CKD.
Materials and Methods
Study Population
We performed serum Cp measures in samples
collected from a prospective cohort of 654 successive
individuals with CKD (estimated GFR [eGFR],60
ml/min per 1.73 m2) presenting for elective diagnos-
tic cardiac evaluations at our health system. The
Receiver operator characteristic curve analyses in the con-
text of the time to event were performed to determine the
optimal cutoff at ,25.5 mg/dl Cp level (which was also
the median Cp level), with a 5-fold cross-validation Cox
model used to estimate risk of event. Using the 5-fold
crossvalidation methods, the data are divided into ﬁve
approximately equally sized portions; the Cox model is
trained on four parts of the data, and then, it estimates
the risk of MACE in the ﬁfth part. This process is repeated
for each of the ﬁve parts, and area under the curve with
the estimated risk is then calculated. This iterative process
was carried out for Cp cutoff values ranging from 19.5 to
34.5 with an increment of 0.1, and the optimal cutoff was
chosen to maximize the C statistics. Quantiﬁcation of
model performance improvement was determined by
both Net Reclassiﬁcation Improvement (NRI) and Inte-
grated Discrimination Improvement, and low-, medium-,
and high-risk category cutoff values for NRI estimation
used a ratio of 6:3:1, respectively. P values represent com-
parison of models with and without Cp. Models adjust-
ment for established risk factors included age, sex,
smoking, HDL cholesterol, systolic BP, history of diabetes
mellitus, triglyceride, eGFR, serum albumin, and BUN.
Survival curves of the two respective Cp groups (serum
Cp,25.5 versus $25.5 mg/dl) were compared with Kaplan
Meier analysis and the log-rank test. Time-to-event analysis
used to determine hazard ratios (HRs) and 95% conﬁdence
intervals (95% CIs) for MACE was determined by Cox pro-
portional hazards regression, and adjustment was made for
established cardiac risk factors, including age, sex, systolic
BP, cigarette smoking, fasting cholesterol values (including
LDL and HDL cholesterol levels), and eGFR. Additional
adjustments incorporated medication use (including angio-
tensin-converting enzyme inhibitors, angiotensin receptor
blockers, b-blockers, and statin therapy), serum albumin,
BUN, history of MI, and history of heart failure to predict
incident 3-year MACE risks. Statistical signiﬁcance was de-
ﬁned as P,0.05 using SAS version 8.2 (Cary, NC) and
R 2.8.0 (Vienna, Austria).
Results
Subject Characteristics
The baseline characteristics for the study population are
presented in Table 1. For the CKD group, mean and me-
dian eGFR were 46613 and 50 ml/min per 1.73 m2 (inter-
quartile range=40 56 ml/min per 1.73 m2), respectively.
Serum Cp in the CKD group was higher compared with
serum Cp in the non-CKD control group (median [inter-
quartile range]; 25.5 [21.8 29.6] versus 22.7 [19.7 26.5]
mg/dl; P,0.001) (Figure 1). Within the CKD group, serum
Cp was correlated with high-sensitivity CRP (r=0.43,
P,0.001), but it did not correlate with indices of renal
function, such as eGFR (r= 0.04, P=0.26) and BUN
(r,0.001, P=0.96).
Serum Cp and Major Adverse Cardiac Outcomes
Within the 3-year follow-up period (median follow-
up=1095 days), a total of 174 events (nonfatal MI, stroke,
or death) was recorded. Dividing Cp as a dichotomous
variable according to the cutoff of 25.5, higher serum Cp
(.25.5 mg/dl) was associated with development of
study? population? was? enrolled? during? 2001? 2006;? they?
were? followed? prospectively? for? 3? years? (median? follow-
up=1095? days),? and? they? consisted? of? only? stable? study?
participants?undergoing?elective?diagnostic?coronary?angi-
ography? (either? cardiac? catheterization? or? coronary? com-
puted? tomography? angiography)? not? in? the? setting? of?
acute? coronary? syndrome? (cardiac? troponin? I,0.03?mg/L).?
No?study?participants?were?on?dialysis.?A?control?group?of?
non-CKD? participants? (eGFR$60?ml/min? per? 1.73? m2,?
n=250)?was? obtained? from? the? same? setting? and?matched?
for? age? and? sex? (1:2.6? versus? the? CKD? group).? Venous?
blood?samples?collected?before?any?heparin?administration?
were?obtained? in?all?study?participants? in?serum?separator?
tubes,? processed,? aliquoted,? and? stored? at? 80°C?within?
4?hours?of?collection.?Written?informed?consent?was?obtained?
for?all?study?participants.?The?Institutional?Review?Board?of?
the?Cleveland?Clinic?approved? the?study?protocols,?and?the?
study?adhered? to? the?Declaration?of?Helsinki.
Study? evaluation? included? assessment? of? standard? car-
diac?risk?factors,?including?age,?sex,?systolic?BP,?and?fasting?
lipids,? as? well? as? history? of? diabetes? mellitus,? cigarette?
smoking,?MI,?or?heart?failure.?eGFR?was?calculated?accord-
ing? to? the? four-variable? equation? of? the? Kidney? Disease?
Outcomes?Quality? Initiative?Modiﬁcation?of?Diet? in?Renal?
Disease?study?guidelines? (11).
End?Points
Deﬁnition?of?major?adverse?cardiovascular?events?(MACEs)?
included? death,? nonfatal? MI,? or? nonfatal? cerebrovascular?
accident.?Study?staff?ascertained?end?points?through?in-person?
follow-up,? which? included? written? solicitation? and? reply?
cards,?medical?chart?review,?and?direct?contact.?Adjudicated?
outcomes?were? collected? for? all? study?participants? over? the?
3-year?follow-up?period.
Serum?Biochemical?Assays
Quantitative?measurement? of?Cp?was?performed?using?
an? immunoturbidimetric? assay? (Abbott? Architect? ci8200;?
Abbott,? Abbott? Park,? IL),? which? yields? high-sensitivity?
measurement?of?Cp?levels.?The?Cp?turbidimetric?procedure?
was? calibrated? at? least? every? 10? days? by? using? multi-
calibrator? material,? which? was? traceable? to? Reference?
Preparation? for?Protein? in?Human?Serum? lot?number?91/?
0619.?During?operation?of?the?Abbott?analyzer,?at?least?two?
levels? of? control?material?were? tested? a?minimum? of? one?
time?per?day.?The? intra-assay? coefﬁcient?of?variation?was?
3.7%,? with? an? interassay? precision? of? up? to? 4%? over? a?
reference?range?of?20? 60?mg/dl.?All?other?assays,?including?
high-sensitivity? C-reactive? protein? (CRP),? creatinine,? and?
fasting?blood?glucose?and? lipid?proﬁles,?were?measured?on?
the?Abbott?Architect?platform?as?previously?described? (12).
Statistical?Analyses
Continuous?variables?were?compared?using?the?t?test?(for?
normal?distribution)?or?Wilcoxon? rank? sum? test? (for?non-
normal? distribution),?whereas? the? chi-squared? test? was?
used? for? categorical? variables.? The? relationship? between?
serum?Cp? levels? and? other? biologic?measures?was? deter-
mined? by? the? Spearman? correlation.? The? log-linearity? as-
sumption?of?Cox?models?was?assessed?by?introduction?of?a?
cubic? spline? component? for? each? continuous? variable.
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not have data, such as proteinuria/albuminuria or follow-up
creatinine, on these patients, we are limited in our ability to
fully characterize their underlying renal disease. Because we
do not have complete Cp polymorphism data on these
patients, we are also unable to assess the contribution of
genetic factors in these patients. Despite these limitations, this
study represents the ﬁrst examination, to our knowledge, of
the contribution of Cp to cardiovascular outcomes in a large
cohort of well characterized patients with moderate CKD.
Although such clinical associative studies do not allow a
complete characterization of the etiology of biomarkers, such
as Cp, they do provide an important framework on which
additional mechanistic studies can build. Because patients
with CKD bear a signiﬁcant burden of oxidative and nitrative
stress, as well as cardiovascular morbidity andmortality, our
ﬁndings merit follow-up examination into this potentially
novel oxidative and nitrative stress pathway in CKD.
Elevated Cp levels are associated with increased risk for
development of adverse cardiac events, including nonfatal
MI, nonfatal stroke, or death, in patients with CKD, even
after multivariable models adjustment for established
clinical and biologic risk factors. These ﬁndings are sup-
portive of the hypothesis that oxidative and nitrative stresses
play a signiﬁcant role in mediating cardiac disease pro-
gression in CKD and point to the potential pro-oxidant role of
Cp in this setting.
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serves? as? a? ferroxidase? that? converts? ferrous? iron? to? a?
nontoxic? ferric? iron,? thus? allowing? for? its?binding? to,? and?
transport?by,?transferrin.?In?this?way,?Cp?serves?to?remove?
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activity?of?myeloperoxidase? (17).?Therefore,? there?may?be?a?
homeostatic? balance? between? pro-oxidant? and? antioxidant?
mechanisms? that?prevails?under?different?conditions.?In?the?
setting?of? limited?NO?availability,? the?NO?oxidase? function?
of?Cp?might?promote? nitrative? stress? and?disease?progres-
sion,?whereas?in?the?setting?of?excessive?oxidant?production,?
the?antioxidant?effects?of?Cp?may?predominate.
The?mechanisms? leading? to? the? Cp? elevations? that?we?
observed? in?patients?with?CKD?remain?unclear.?Tubuloin-
terstitial?and?glomerular?hypoxia?are?important?factors?that?
accelerate? renal? disease? (18),? and? recent? studies? have? ob-
served? that?activation?of?Cp? expression? is?mechanistically?
linked? to? a? hypoxia-inducible? factor,?where? hypoxia? re-
sponse? element? dependent?gene? regulation? leads? to? tran-
scriptional? induction?of? the?Cp?gene?promoter? (19).?These?
data,? together?with? the? intermittent?but?recurring?hypoxia?
in? the? setting? of?CKD? (20),? suggest? that? extrinsic? factors,?
such? as? hypoxia,?may? be? responsible? for?modulating?Cp?
levels?in?patients?with?CKD.?Furthermore,?in?a?rat?model?of?
age-associated? glomerulosclerosis,? caloric? restriction? pre-
vented?elevations? in?both?secreted?Cp?and?Bowman’s cap-
sule?Cp? expression? and? reduced? glomerulosclerosis? at? 24?
months?(21).?It?was?further?shown?that?NF-kB?p50?binds?to?
the?kB?motif?of?Cp?expressed? in? the?parietal?epithelium? in?
old?versus?young?glomeruli,?suggesting?an?age-associated?
NF-kB? driven?process? (22).
Although? Cp? has? established? links? with? measures? of?
systemic?oxidant/nitrative?stress?and?cardiovascular?risk?in?
patients?with?normal?renal?function?(5? 10),?we?now?report?
that? serum? Cp? levels?may? be? prognostically? important?
within? a? large? cohort? of? patients? with? moderate? CKD?
and? prospective? long-term? clinical? event? data.?Our? ﬁnd-
ings? suggest? that?Cp?may?be?a?potentially? important? reg-
ulator?of?oxidative?and?nitrative?stress? that? is? increased? in?
patients?with?moderately? reduced? renal? function.?Because?
Cp? is? readily?measured? in? any? clinical? chemistry? labora-
tory,?it?may?be?a?clinically?useful?diagnostic?and?therapeu-
tic?target?in?the?setting?of?CKD,?because?treatment?options?
that?address?the?signiﬁcant?burden?of?cardiovascular?mor-
bidity?and?mortality?in?these?patients?are?limited.?Our?ﬁnd-
ings? suggest? that? speciﬁc? oxidative? and? nitrative? stress?
pathways,? such?as? those?pathways? catalyzed?by?Cp,?may?
be?an?important?modiﬁer?of?cardiovascular?risk?in?patients?
with?moderate? CKD,? and? thus,? it? is? a? relevant? topic? for?
future?mechanistic? investigation.
Study?Limitations
The?selection?of?stable?stage?3?CKD?patients?with?suspect?
coronary? disease?may? introduce? a? selection? bias? that? po-
tentially? confounds? interpretation? of? such? case-control?
studies.? Serum? Cp? was? also? only? measured? at? a? single?
time?point,?and,?as?such,?we?have? limited?ability? to?detect?
the?inﬂuence?of?therapeutic?effects?on?Cp?levels?over?time?or?
whether?changes?in?Cp?levels?over?time?are?also?of?prognostic?
importance?to?patients?with?CKD.?Similarly,?because?we?do
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